Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.


PINL:BCEL - Post by User

Bullboard Posts
Post by sweatmanon Jun 19, 2013 1:52pm
242 Views
Post# 21543280

Just in...

Just in...

.....according to one analyst:

On June 18th, Colossus Minerals (CSI) provided a development update on the company's 75%-owned Serra Pelada gold-platinum-palladium project in Brazil. In short, the update highlighted the positive progress being made as the company works towards its initial production timeline which CSI has set for Q3/13. With construction progressing to plan, the bulk sample extraction nearing completion and the balance sheet buffered after the recent equity issuance, our confidence in CSI continues to grow. But despite the progress to date and project's risk profile declining, CSI's share price is trading near a 52-week low. As a result, we believe an opportunity has emerged for investors to consider building a position in the name and given the recent insider buying, it seems company insiders agree.   Hence, we reiterate our BUY rating at this time. We have however, adjusted our  12-month target to $4.00  (from $4.25) to reflect a higher royalty rate which is being tabled as part of Brazil's mining code revisions.

Bullboard Posts